David Meek has served as Chairman of the Board since June 2019. David has been CEO of Ipsen Pharmaceuticals since July 2016 and is also on the Board of Directors of Ipsen. David has over 25 years of experience in the pharmaceutical industry where he has held various global executive positions in major pharmaceutical and biotechnology companies. Prior to joining Ipsen, David was executive vice-president and president of the oncology division of Baxalta Inc.
David started his biopharma career at Johnson & Johnson and Janssen Pharmaceuticals (1989-2004) where he held a variety of senior US sales and marketing positions across therapeutic areas in primary care, specialty care, and oncology.
He then joined Novartis International AG (2005-2012), where he successively served as the global business franchise head for the company’s respiratory and dermatology franchise in Basel, Switzerland; president and chief executive officer of the pharmaceutical division in Canada; and the head of oncology for Northern, Central and Eastern Europe. From 2012 to 2014, he served as chief commercial officer of Endocyte Inc, an oncology biotechnology company.
Prior to his biopharma career David was an officer in the United States Army. He is a graduate of the University of Cincinnati.
David serves on the Boards of uniQure, PhRMA, EFPIA and Camping and Education Foundation.
Manos Perros, PhD
President and Chief Executive Officer
Manos Perros, Ph.D., has served as our chief executive officer, co-founder and director since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer’s Award in 2010.
Nicholas Galakatos, PhD
Nicholas Galakatos, Ph.D., has served on our board of directors since March 2016.
Nicholas Galakatos is the Head of the Blackstone Life Sciences business, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Dr. Galakatos was a co-founder and managing director of Clarus since the firm's inception in 2005. Dr. Galakatos has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage companies. Prior to Clarus, Dr. Galakatos was a general partner at MPM Capital, a healthcare venture capital firm. From 1997 to 2000 he was Vice president of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the management team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the chairman and founding CEO. Prior to Millennium he was at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Ciba-Geigy (presently Novartis). Dr. Galakatos is currently the chairman of the board of Anthos Therapeutics and Praxis Precision Medicine, and a member of the board of directors of Nanostring Technologies (NADASQ: NSTG), Nuvelution Pharma, Inc., and Talaris, Inc. He is a member of the Director's Council of the Koch Institute at MIT and a member of the Board of Trustees at Reed College.
Gregory Norden has served as a member of our board of directors since October 2016. From 1989 to 2010, Mr. Norden held various senior positions at Wyeth/American Home Products, most recently as Wyeth’s senior vice president and chief financial officer. Mr. Norden currently serves on the boards of directors of Nanostring Technologies, Inc., Royalty Pharma, Univision and Zoetis Inc. Mr. Norden previously served as a director of Welch Allyn, Inc. (acquired by Hill-Rom, Inc. in 2015), Lumara Health Inc. (acquired by AMAG Pharmaceuticals in 2014), and Human Genome Sciences Inc. (acquired by GlaxoSmithKline plc in 2012). Mr. Norden received a M.S. in Accounting from Long Island University—C.W. Post and a B.S. in Management/Economics from the State University of New York—Plattsburgh.
Heather Behanna, PhD
Heather Behanna, Ph.D., has served as a member of our board of directors since August 2017. Dr. Behanna was a principal at Sofinnova Investments from January 2017 to November 2018, focusing on biopharmaceutical investments. Prior to joining Sofinnova, Dr. Behanna was a senior vice president and biotechnology sell-side analyst at Wedbush Securities from August 2014 to December 2016, preceded by a role as an associate at JMP Securities from September 2010 to June 2014. Prior to this, Dr. Behanna worked in early stage drug discovery at the Astellas Research Institute and was also an adjunct professor at the Feinberg School of Medicine at Northwestern University. Dr. Behanna received her Ph.D. in Chemistry from Northwestern University, an M.S. in Organic Chemistry from the Weizmann Institute of Science and her B.S. from Tufts University.
Heather Preston, MD
Heather Preston, M.D., has served as a member of our board of directors since August 2017. Dr. Preston is a Managing Partner at Pivotal Bioventures and a Senior Advisor to TPG Biotech. From 2005-2018, Dr. Preston was a Partner and Managing Director of TPG BioTech. Prior to that, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at J.P. Morgan Partners, LLC, a private equity firm, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, and was a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. Dr. Preston currently serves on the boards of directors of Oxford Biomedica (OXB), Alder BioPharmaceuticals, Inc., Otonomy, Inc. and a number of private companies. Dr. Preston received her M.D. from the University of Oxford and a B.S. in Biochemistry from the University of London.
David C. Hastings
David C. Hastings has served as a member of our board of directors since April 2018. Mr. Hastings served as the senior vice president and chief financial officer of Unilife Corporation from February 2015 to June 2017 and as Unilife’s Chief Accounting Officer and Treasurer from July 2016 to June 2017. From October 2003 to October 2014, Mr. Hastings served as executive vice president and chief financial officer at Incyte Corporation. Mr. Hastings currently serves on the board of directors of Scynexis Inc. and VBL Therapeutics Ltd. Mr. Hastings received his B.A. in Economics at the University of Vermont.
Howard Mayer, MD
Howard Mayer, M.D. has served as a member of our board of directors since August 2019. Dr. Mayer was most recently senior vice president, chief medical officer and global head of R&D, Neuroscience Division at Shire Pharmaceuticals. Previously, Howard was senior vice president and head of Global Clinical Development at Shire. Dr. Mayer joined Shire in 2012 and in his prior role at Shire was responsible for global clinical development (Phase I-IV) across the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas. He was also responsible for clinical development operations, clinical pharmacology, and medical devices. Previously he served as chief medical officer at EMD Serono, a division of Merck KGaA, since 2009. Prior to that, he held a variety of global roles at Pfizer Inc. over nearly eight years, including head of clinical development and medical affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as director of Infectious Diseases Clinical Research at Bristol-Myers Squibb for five years. Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences, and has served on the board of Autism Speaks in New England since 2011 and on the board of the Melmark Charitable Foundation since 2016. In 2011 and in 2017, he was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry.